Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.
What happened
FDA inspected Auriga Research's contract testing laboratory in Bengaluru, India, from February 4 to 6, 2026. Investigators found incomplete raw data for microbial tests—raw test sheets had blank spaces and did not fully document plate counts—and quality unit approval of inadequate investigations into failing test results. The firm said some samples were not for the U.S. market, but FDA noted the same quality system and procedures are used for all drugs the lab tests, including U.S. drugs.
What FDA found
Laboratory records for microbial tests were incomplete: raw data sheets had blank spaces and did not fully document plate counts even though summary reports listed final counts.
21 CFR 211.194(a)The lab did not complete records at the time it performed the tests.
21 CFR 211.194(a)The quality unit approved investigations that did not adequately establish root causes or ensure corrective and preventive actions were justified and implemented.
21 CFR 211.22(d)For failing assay and impurity tests, the lab repeatedly retested until it got passing results and invalidated failures without scientific justification, a practice FDA called “testing into compliance.”
21 CFR 211.22(d)The quality unit's written responsibilities and procedures were inadequate to oversee investigations and ensure drug testing quality.
21 CFR 211.22(d)
What FDA wants
FDA tells Auriga to send a written response within 15 business days of receipt, identified with FEI 3019975128 and ATTN: Compliance Officer Barbara Wilimczyk-Macri. The response must include comprehensive assessments and remediation plans for laboratory practices, documentation and data integrity, microbial sample handling, quality unit authority and oversight, investigations, CAPA, and a three-year retrospective review of OOS results for U.S. products.
Who should pay attention
- drug manufacturers and sponsors that use Auriga for testing
- brands selling U.S. drug products tested by Auriga
- quality teams relying on contract lab data for release or applications
This is a summary. Read the original letter on fda.gov.